Intra-Cellular Therapies (ITCI) Stock Forecast, Price Target & Predictions
ITCI Stock Forecast
Intra-Cellular Therapies stock forecast is as follows: an average price target of $94.00 (represents a 24.70% upside from ITCI’s last price of $75.38) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
ITCI Price Target
The average price target for Intra-Cellular Therapies (ITCI) is $94.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $107.00 to $70.00. This represents a potential 24.70% upside from ITCI's last price of $75.38.
ITCI Analyst Ratings
According to 7 Wall Street analysts, Intra-Cellular Therapies's rating consensus is 'Buy'. The analyst rating breakdown for ITCI stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Intra-Cellular Therapies Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 05, 2024 | David Amsellem | Piper Sandler | $92.00 | $72.42 | 27.04% | 22.05% |
| Aug 08, 2024 | Brian Abrahams | RBC Capital | $106.00 | $73.63 | 43.96% | 40.62% |
| Aug 07, 2024 | Corinne Jenkins | Goldman Sachs | $74.00 | $73.63 | 0.50% | -1.83% |
| Jul 22, 2024 | Ami Fadia | Needham | $100.00 | $74.86 | 33.58% | 32.66% |
| Jun 25, 2024 | Ashwani Verma | UBS | $83.00 | $72.42 | 14.61% | 10.11% |
| Jun 20, 2024 | Graig Suvannavejh | Mizuho Securities | $100.00 | $76.06 | 31.48% | 32.66% |
| Jun 18, 2024 | Brian Abrahams | RBC Capital | $103.00 | $75.48 | 36.46% | 36.64% |
| May 07, 2024 | Brian Abrahams | RBC Capital | $96.00 | $71.21 | 34.81% | 27.35% |
| May 07, 2024 | Andrew Tsai | Jefferies | $105.00 | $70.08 | 49.84% | 39.29% |
| Apr 23, 2024 | Sumant Kulkarni | Canaccord Genuity | $107.00 | $74.54 | 43.55% | 41.95% |
The latest Intra-Cellular Therapies stock forecast, released on Sep 05, 2024 by David Amsellem from Piper Sandler, set a price target of $92.00, which represents a 27.04% increase from the stock price at the time of the forecast ($72.42), and a 22.05% increase from ITCI last price ($75.38).
Intra-Cellular Therapies Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 7 | 12 |
| Avg Price Target | $92.00 | $94.00 | $95.92 |
| Last Closing Price | $75.38 | $75.38 | $75.38 |
| Upside/Downside | 22.05% | 24.70% | 27.25% |
In the current month, the average price target of Intra-Cellular Therapies stock is $92.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 22.05% increase as opposed to Intra-Cellular Therapies's last price of $75.38. This month's average price target is down -2.13% compared to last quarter, and down -4.09% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | UBS | Buy | Buy | Hold |
| Sep 06, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Sep 05, 2024 | Piper Sandler | - | Overweight | Upgrade |
| Aug 08, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Aug 07, 2024 | Goldman Sachs | Neutral | Neutral | Hold |
| Jul 22, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Jul 22, 2024 | UBS | Buy | Buy | Hold |
| Jul 22, 2024 | Needham | Buy | Buy | Hold |
| Jun 25, 2024 | UBS | Buy | Neutral | Downgrade |
| Jun 25, 2024 | RBC Capital | Outperform | Outperform | Hold |
Intra-Cellular Therapies's last stock rating was published by UBS on Sep 06, 2024. The company gave ITCI a "Buy" rating, the same as its previous rate.
Intra-Cellular Therapies Financial Forecast
Intra-Cellular Therapies Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | Mar 18 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $126.17M | $110.79M | $94.73M | $87.43M | $71.87M | - | $34.76M | $25.52M | $21.61M | $19.01M | $15.58M | $12.40M | $7.37M | $1.88M | $882.52K | - | - | - | - | - | $30.75K |
| Avg Forecast | $259.96M | $232.14M | $210.38M | $195.43M | $188.55M | $172.24M | $157.90M | $141.41M | $135.68M | $119.25M | $106.45M | $92.11M | $87.01M | $65.99M | $49.04M | $33.66M | $25.03M | $22.08M | $19.03M | $16.70M | $11.82M | $5.53M | $2.92M | $1.44M | $12.50K | $14.29K | $12.50K | $7.42B | $6.48B | $35.98K |
| High Forecast | $264.53M | $236.22M | $214.09M | $198.87M | $191.87M | $178.38M | $160.68M | $143.89M | $139.18M | $123.17M | $108.32M | $93.73M | $88.54M | $67.16M | $49.04M | $34.96M | $25.99M | $22.93M | $19.77M | $17.35M | $12.28M | $5.74M | $3.03M | $1.50M | $12.98K | $14.84K | $12.98K | $8.91B | $7.78B | $43.17K |
| Low Forecast | $249.03M | $222.38M | $201.54M | $187.21M | $180.63M | $165.03M | $151.26M | $135.46M | $130.25M | $115.50M | $101.97M | $88.24M | $83.35M | $63.22M | $49.04M | $32.52M | $24.19M | $21.33M | $18.39M | $16.14M | $11.43M | $5.34M | $2.82M | $1.39M | $12.08K | $13.80K | $12.08K | $5.94B | $5.18B | $28.78K |
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 8 | 4 | 7 | 4 | 4 | 5 | 3 | 3 | 9 | 9 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 1.03% | 1.00% | 1.09% | - | 1.03% | 1.02% | 0.98% | 1.00% | 0.93% | 1.05% | 1.33% | 0.64% | 0.61% | - | - | - | - | - | 0.85% |
Intra-Cellular Therapies's average Quarter revenue forecast for Dec 23 based on 5 analysts is $135.68M, with a low forecast of $130.25M, and a high forecast of $139.18M. ITCI's average Quarter revenue forecast represents a 7.54% increase compared to the company's last Quarter revenue of $126.17M (Sep 23).
Intra-Cellular Therapies EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | Mar 18 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 8 | 4 | 7 | 4 | 4 | 5 | 3 | 3 | 9 | 9 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-29.71M | $-47.18M | $-48.39M | $-47.41M | $-55.46M | - | $-72.49M | $-85.86M | $-77.19M | $-69.02M | $-53.09M | $-61.21M | $-55.82M | $-64.74M | $-48.94M | $-36.25M | $-39.07M | $-36.59M | $-39.07M | $-37.00M | $-22.82M |
| Avg Forecast | $-225.84M | $-201.67M | $-182.77M | $-169.78M | $-163.80M | $-149.63M | $-137.17M | $-71.91M | $-117.87M | $-103.59M | $-92.47M | $-76.91M | $-75.59M | $-90.60M | $-42.60M | $-82.26M | $-21.74M | $-71.62M | $-63.38M | $-62.47M | $-66.98M | $-66.63M | $-60.09M | $-57.42M | $-43.95M | $-46.13M | $-46.69M | $-42.72M | $-37.56M | $-26.13M |
| High Forecast | $-216.34M | $-193.19M | $-175.09M | $-162.64M | $-156.92M | $-143.37M | $-131.41M | $-57.53M | $-113.15M | $-100.34M | $-88.59M | $-61.53M | $-72.41M | $-72.48M | $-42.60M | $-65.81M | $-21.01M | $-57.30M | $-50.71M | $-49.98M | $-53.58M | $-53.30M | $-48.07M | $-45.94M | $-35.16M | $-36.90M | $-37.35M | $-34.18M | $-30.05M | $-20.91M |
| Low Forecast | $-229.81M | $-205.22M | $-185.99M | $-172.76M | $-166.69M | $-154.97M | $-139.59M | $-86.30M | $-120.91M | $-107.01M | $-94.10M | $-92.30M | $-76.92M | $-108.72M | $-42.60M | $-98.71M | $-22.58M | $-85.94M | $-76.06M | $-74.97M | $-80.37M | $-79.95M | $-72.10M | $-68.91M | $-52.74M | $-55.35M | $-56.03M | $-51.26M | $-45.07M | $-31.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.29% | 0.51% | 0.63% | 0.63% | 0.61% | - | 0.88% | 3.95% | 1.08% | 1.09% | 0.85% | 0.91% | 0.84% | 1.08% | 0.85% | 0.82% | 0.85% | 0.78% | 0.91% | 0.99% | 0.87% |
undefined analysts predict ITCI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Intra-Cellular Therapies's previous annual EBITDA (undefined) of $NaN.
Intra-Cellular Therapies Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | Mar 18 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 8 | 4 | 7 | 4 | 4 | 5 | 3 | 3 | 9 | 9 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | $-24.26M | $-42.78M | $-44.05M | $-37.25M | $-53.51M | - | $-72.12M | $-85.19M | $-76.91M | $-68.74M | $-52.74M | $-60.70M | $-53.68M | $-61.39M | $-47.41M | $-33.35M | $-37.44M | $-32.98M | $-37.38M | $-33.88M | $-22.87M |
| Avg Forecast | $30.43M | $12.45M | $-2.90M | $-12.45M | $-9.89M | $-18.03M | $-19.73M | $-72.64M | $-46.77M | $-58.64M | $-61.21M | $-77.69M | $-61.44M | $-90.73M | $-73.60M | $-83.09M | $-96.85M | $-71.72M | $-63.52M | $-62.63M | $-67.13M | $-66.77M | $-60.21M | $-57.61M | $-42.27M | $-44.21M | $-44.45M | $-40.86M | $-36.02M | $-26.19M |
| High Forecast | $31.12M | $12.73M | $-2.75M | $-11.77M | $-9.35M | $-7.43M | $-18.65M | $-58.11M | $-40.39M | $-48.17M | $-57.86M | $-62.15M | $-58.08M | $-72.58M | $-73.60M | $-66.47M | $-92.61M | $-57.38M | $-50.82M | $-50.10M | $-53.70M | $-53.42M | $-48.17M | $-46.09M | $-33.82M | $-35.37M | $-35.56M | $-32.69M | $-28.81M | $-20.95M |
| Low Forecast | $28.76M | $11.77M | $-2.97M | $-12.73M | $-10.12M | $-27.58M | $-20.18M | $-87.17M | $-54.21M | $-65.98M | $-62.61M | $-93.23M | $-62.85M | $-108.88M | $-73.60M | $-99.71M | $-101.72M | $-86.07M | $-76.23M | $-75.15M | $-80.55M | $-80.13M | $-72.25M | $-69.13M | $-50.72M | $-53.05M | $-53.33M | $-49.04M | $-43.22M | $-31.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.41% | 0.70% | 0.57% | 0.61% | 0.59% | - | 0.87% | 0.88% | 1.07% | 1.08% | 0.84% | 0.90% | 0.80% | 1.02% | 0.82% | 0.79% | 0.85% | 0.74% | 0.91% | 0.94% | 0.87% |
Intra-Cellular Therapies's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ITCI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Intra-Cellular Therapies SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | Mar 18 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 8 | 4 | 7 | 4 | 4 | 5 | 3 | 3 | 9 | 9 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | $105.21M | $101.01M | $98.92M | $94.63M | $88.38M | - | $75.46M | $79.68M | $70.50M | $69.85M | $52.58M | $58.35M | $52.47M | $41.45M | $34.10M | $15.04M | $15.44M | $11.70M | $6.73M | $6.38M | $5.32M |
| Avg Forecast | $56.43B | $50.39B | $45.67B | $42.43B | $40.93B | $37.39B | $34.28B | $76.01M | $29.46B | $25.89B | $23.11B | $81.29M | $18.89B | $14.33B | $10.65B | $7.31B | $5.43B | $4.79B | $4.13B | $3.63B | $2.57B | $1.20B | $633.09M | $312.58M | $2.71M | $3.10M | $2.71M | $7.36M | $6.48M | $7.81M |
| High Forecast | $57.43B | $51.28B | $46.48B | $43.17B | $41.65B | $38.72B | $34.88B | $91.21M | $30.21B | $26.74B | $23.52B | $97.55M | $19.22B | $14.58B | $10.65B | $7.59B | $5.64B | $4.98B | $4.29B | $3.77B | $2.67B | $1.25B | $657.57M | $324.67M | $2.82M | $3.22M | $2.82M | $8.83M | $7.77M | $9.37M |
| Low Forecast | $54.06B | $48.28B | $43.75B | $40.64B | $39.21B | $35.83B | $32.84B | $60.81M | $28.28B | $25.07B | $22.14B | $65.03M | $18.09B | $13.72B | $10.65B | $7.06B | $5.25B | $4.63B | $3.99B | $3.50B | $2.48B | $1.16B | $611.79M | $302.07M | $2.62M | $3.00M | $2.62M | $5.89M | $5.18M | $6.25M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 1.22% | 0.01% | 0.01% | - | 0.01% | 0.01% | 0.01% | 0.02% | 0.01% | 0.02% | 0.04% | 0.07% | 0.11% | 5.54% | 4.98% | 4.31% | 0.91% | 0.99% | 0.68% |
Intra-Cellular Therapies's average Quarter SG&A projection for Dec 23 is $29.46B, based on 5 Wall Street analysts, with a range of $28.28B to $30.21B. The forecast indicates a 27897.32% rise compared to ITCI last annual SG&A of $105.21M (Sep 23).
Intra-Cellular Therapies EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | Mar 18 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 8 | 4 | 7 | 4 | 4 | 5 | 3 | 3 | 9 | 9 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.25 | $-0.00 | $-0.46 | $-0.39 | $-0.57 | - | $-0.78 | $-1.05 | $-0.95 | $-0.85 | $-0.65 | $-0.76 | $-0.77 | $-0.92 | $-0.73 | $-0.60 | $-0.68 | $-0.60 | $-0.68 | $-0.62 | $-0.53 |
| Avg Forecast | $0.29 | $0.12 | $-0.03 | $-0.12 | $-0.10 | $-0.17 | $-0.19 | $-0.32 | $-0.45 | $-0.57 | $-0.59 | $-0.61 | $-0.59 | $-0.81 | $-0.76 | $-0.92 | $-1.01 | $-0.93 | $-0.79 | $-0.79 | $-0.85 | $-1.00 | $-0.91 | $-0.93 | $-0.80 | $-0.83 | $-0.87 | $-0.82 | $-0.67 | $-0.71 |
| High Forecast | $0.30 | $0.12 | $-0.03 | $-0.11 | $-0.09 | $-0.07 | $-0.18 | $-0.30 | $-0.39 | $-0.46 | $-0.56 | $-0.57 | $-0.56 | $-0.77 | $-0.76 | $-0.88 | $-0.96 | $-0.88 | $-0.76 | $-0.76 | $-0.81 | $-0.95 | $-0.87 | $-0.89 | $-0.77 | $-0.80 | $-0.83 | $-0.66 | $-0.54 | $-0.57 |
| Low Forecast | $0.28 | $0.11 | $-0.03 | $-0.12 | $-0.10 | $-0.27 | $-0.19 | $-0.32 | $-0.52 | $-0.64 | $-0.60 | $-0.62 | $-0.61 | $-0.83 | $-0.76 | $-0.97 | $-1.06 | $-0.97 | $-0.83 | $-0.83 | $-0.89 | $-1.05 | $-0.95 | $-0.97 | $-0.84 | $-0.87 | $-0.91 | $-0.98 | $-0.80 | $-0.85 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.44% | 0.00% | 0.76% | 0.66% | 0.70% | - | 0.85% | 1.04% | 1.03% | 1.07% | 0.82% | 0.90% | 0.77% | 1.01% | 0.79% | 0.75% | 0.82% | 0.69% | 0.83% | 0.93% | 0.75% |
According to undefined Wall Street analysts, Intra-Cellular Therapies's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ITCI previous annual EPS of $NaN (undefined).
Intra-Cellular Therapies Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PCRX | Pacira BioSciences | $13.11 | $43.00 | 227.99% | Hold |
| IRWD | Ironwood Pharmaceuticals | $4.57 | $11.67 | 155.36% | Buy |
| DVAX | Dynavax | $11.17 | $24.50 | 119.34% | Buy |
| AQST | Aquestive Therapeutics | $4.84 | $9.50 | 96.28% | Buy |
| CYTH | Cyclo Therapeutics | $0.65 | $0.95 | 46.15% | Buy |
| AMPH | Amphastar Pharmaceuticals | $48.09 | $66.00 | 37.24% | Buy |
| ALKS | Alkermes | $27.66 | $35.50 | 28.34% | Buy |
| ITCI | Intra-Cellular Therapies | $75.38 | $94.00 | 24.70% | Buy |
| NBIX | Neurocrine Biosciences | $122.25 | $146.60 | 19.92% | Buy |
| ANIP | ANI Pharmaceuticals | $58.51 | $67.33 | 15.07% | Buy |
| COLL | Collegium Pharmaceutical | $37.50 | $41.50 | 10.67% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| AMRX | Amneal Pharmaceuticals | $8.62 | $7.00 | -18.79% | Buy |
ITCI Forecast FAQ
Is Intra-Cellular Therapies a good buy?
Yes, according to 7 Wall Street analysts, Intra-Cellular Therapies (ITCI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of ITCI's total ratings.
What is ITCI's price target?
Intra-Cellular Therapies (ITCI) average price target is $94 with a range of $70 to $107, implying a 24.70% from its last price of $75.38. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Intra-Cellular Therapies stock go up soon?
According to Wall Street analysts' prediction for ITCI stock, the company can go up by 24.70% (from the last price of $75.38 to the average price target of $94), up by 41.95% based on the highest stock price target, and down by -7.14% based on the lowest stock price target.
Can Intra-Cellular Therapies stock reach $110?
ITCI's average twelve months analyst stock price target of $94 does not support the claim that Intra-Cellular Therapies can reach $110 in the near future.
What is Intra-Cellular Therapies's current price target trend?
1 Wall Street analyst forecast a $92 price target for Intra-Cellular Therapies (ITCI) this month, up 22.05% from its last price of $75.38. Compared to the last 3 and 12 months, the average price target increased by 24.70% and increased by 27.25%, respectively.
What are Intra-Cellular Therapies's analysts' financial forecasts?
Intra-Cellular Therapies's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $660.1M (high $674.82M, low $632.38M), average EBITDA is $-523M (high $-489M, low $-548M), average net income is $-120M (high $-93.546M, low $-145M), average SG&A $112.68B (high $115.35B, low $107.94B), and average EPS is $-0.777 (high $-0.642, low $-0.883). ITCI's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $897.91M (high $913.71M, low $860.17M), average EBITDA is $-780M (high $-747M, low $-794M), average net income is $27.52M (high $29.34M, low $24.83M), average SG&A $194.93B (high $198.36B, low $186.73B), and average EPS is $0.265 (high $0.283, low $0.239).
Did the ITCI's actual financial results beat the analysts' financial forecasts?
Based on Intra-Cellular Therapies's last annual report (Dec 2022), the company's revenue was $249.13M, beating the average analysts forecast of $235.69M by 5.70%. Apple's EBITDA was $-264M, missing the average prediction of $-291M by -9.42%. The company's net income was $-256M, missing the average estimation of $-309M by -17.03%. Apple's SG&A was $358.78M, missing the average forecast of $51.17B by -99.30%. Lastly, the company's EPS was $-2.72, missing the average prediction of $-3.086 by -11.87%. In terms of the last quarterly report (Sep 2023), Intra-Cellular Therapies's revenue was $126.17M, beating the average analysts' forecast of $119.25M by 5.81%. The company's EBITDA was $-29.713M, missing the average prediction of $-104M by -71.32%. Intra-Cellular Therapies's net income was $-24.258M, missing the average estimation of $-58.645M by -58.64%. The company's SG&A was $105.21M, missing the average forecast of $25.89B by -99.59%. Lastly, the company's EPS was $-0.25, missing the average prediction of $-0.565 by -55.78%